BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. - Wikidata - awgldk - TriplyDB

BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.

BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.

http://www.wikidata.org/entity/Q48499411

about

Current State of Animal (Mouse) Modeling in Melanoma Research Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets Targeting melanoma by small molecules: challenges ahead Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance Melanoma brain metastases: an unmet challenge in the era of active therapy BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis Melanoma Brain Metastasis: Mechanisms, Models, and Medicine Function and Clinical Implications of Long Non-Coding RNAs in Melanoma.BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies.Discrepant alterations in main candidate genes among multiple primary melanomas MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor.Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients.Molecular alterations in clinical stage III cutaneous melanoma: Correlation with clinicopathological features and patient outcome.Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy.Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.Tumour heterogeneity in the clinic.Oncogenic codon 13 NRAS mutation in a primary mesenchymal brain neoplasm and nevus of a child with neurocutaneous melanosis.Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site.The MAPK pathway across different malignancies: a new perspective.The molecular genomics of metastatic brain tumours.Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations.Genotyping of cutaneous melanoma.Update on Molecular Pathology of Cutaneous Melanocytic Lesions: What is New in Diagnosis and Molecular Testing for Treatment?Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas.BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma Molecular and genetic diversity in the metastatic process of melanoma Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines.Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract.A primary melanoma and its asynchronous metastasis highlight the role of BRAF, CDKN2A, and TERT A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.The immune-related role of BRAF in melanoma.NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.SOX5 is involved in balanced MITF regulation in human melanoma cells.A combination of high dose rate (10X FFF/2400 MU/min/10 MV X-rays) and total low dose (0.5 Gy) induces a higher rate of apoptosis in melanoma cells in vitro and superior preservation of normal melanocytes.BRAFV600E immunopositive melanomas show low frequency of heterogeneity and association with epithelioid tumor cells: a STROBE-compliant article.Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.Competitive allele-specific TaqMan PCR (Cast-PCR) is a sensitive, specific and fast method for BRAF V600 mutation detection in Melanoma patients.Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma

P2860

Q26781652-62B0DC3E-E9A6-4815-8028-6E7A1361EE83 Q26795735-2A3A64E4-4760-4D26-AE99-4E4A13CCE1AC Q26824642-2FA0E494-0414-4F87-8D25-5B207B2108B0 Q26866517-EFD2A248-6D5A-4307-AB41-18E96A2FF5CB Q26995622-1D5A491D-0F57-42FA-AB5E-02D3C46B90D8 Q27852927-DF1BC9B2-78EC-4E77-B044-32CEC403A92B Q28066914-4EE35A20-74A9-4AC3-907B-DE8CF1A96CE7 Q28069421-AFA38DE8-56FF-46DD-BC01-4979C3170255 Q30313298-5D5D8F45-6B57-49EA-9405-3FD2F2A25D7B Q30458424-154F38D0-F6F0-4BE8-BC3F-62BC8E879A55 Q30578299-875DF5D0-A96A-4E0B-B4F0-A89F2F1B8C41 Q33566681-DDD2F9C2-D7AF-431C-A3DF-558790D3DE20 Q33650820-ECC74233-05F2-47EB-88E2-397D03897455 Q33778554-B04A2B05-75E6-4EBC-B60D-CCA313B2381F Q33917630-E3C1F809-D079-4A26-AE1B-C756695CA68F Q34341465-2B575E86-3B3E-42D9-8870-8A5F73F16CDC Q34372080-69056241-452A-4D79-B987-292AA25341A8 Q34402363-A6614EDF-3D54-4DB8-BFD8-D98D955F1B95 Q34446657-1BC2DC58-1A00-495C-B105-FDA0984D6F82 Q34459097-7C384EBB-AB8D-45C9-9052-73393CE446B4 Q34499855-B503EA77-EA53-4CF5-9E63-518122853F2C Q34547540-D1B31E5C-C857-4073-BBA5-69FEBE3CB647 Q34667738-B39E6A53-25A8-4169-A992-F39A503A90C8 Q34928118-BF3D4EFE-8BF1-4B6E-A15F-70B887098B3C Q34970350-7BA2AA70-928C-449B-AC04-9D037592CE7D Q35033377-FC544674-BEB1-4EC0-8488-EA3DCF55F5B1 Q35141834-D3AF7F4C-68AE-4E49-AD91-5884DEF21316 Q35177775-D8BFA054-0EB5-48F2-A12C-F9788A104EAC Q35206543-A3948373-8374-486D-A7FF-DB7892CCD6A8 Q35670595-4390FA7C-F189-43EC-BD0B-DDAB30CBEC14 Q35751775-545FA26D-22D5-4C18-B80B-695AF882E322 Q35820476-E20D1F83-B3FF-4E19-930A-43EAE9E1CBD9 Q35847321-566E4E81-7F90-4C4C-A020-5A09E2104263 Q35885523-EE6D9B6E-9114-4EE7-A6FF-A91301AE7E84 Q35939947-B82BE7D4-77F4-4BDC-AF41-D10E0B0F1C6F Q36028539-4362F7AD-23B7-48F9-84F5-D0E1E300D476 Q36154050-0876B1D4-9D74-459B-8725-155B7B4CBAD4 Q36260662-A66AA5E9-7C96-4BA0-8A9D-3185DA7C38BB Q36392912-49D89FED-A428-43DA-8BB8-39E130E96093 Q36545907-5A645448-A56F-46DC-A600-BF3DEE354D18

P2860

BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.

http://www.wikidata.org/entity/Q48499411

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

BRAF/NRAS mutation frequencies ...... ses in patients with melanoma.

@en

BRAF/NRAS mutation frequencies ...... ses in patients with melanoma.

@nl

type

label

BRAF/NRAS mutation frequencies ...... ses in patients with melanoma.

@en

BRAF/NRAS mutation frequencies ...... ses in patients with melanoma.

@nl

prefLabel

BRAF/NRAS mutation frequencies ...... ses in patients with melanoma.

@en

BRAF/NRAS mutation frequencies ...... ses in patients with melanoma.

@nl

P1433

Q48499411-0E74D1AA-10F7-40F8-B10D-8F4C15A30219

P1476

Q48499411-1AB3F966-4DFD-4D5D-B880-B0EE2B2FCC63

P2093

Q48499411-02BF8665-5598-4001-82A5-8227FE397647

Q48499411-4DAE46D4-C754-452B-98CF-5B2D878615E4

Q48499411-5567BB27-8611-445E-9169-D38BF2D06B79

Q48499411-578250D8-F847-4728-8ED3-C1A1A98E1111

Q48499411-68C5A878-13C3-41B4-B94D-6DB47CCB4692

Q48499411-74BC9CB2-99C1-46B5-9579-67586AC27BB9

Q48499411-7D7E62F1-25C2-4414-AB6A-C978FC8B6F57

Q48499411-A520A016-99DF-4270-86E8-75B3CA019ED4

Q48499411-AD90FEBB-09C0-44E2-BC5E-7C227ED46249

Q48499411-C6D6C07B-DFCD-4672-ACD1-E44D8E603C80

P304

Q48499411-4BFB5D3C-FDB5-4ADA-A56D-520EB9674F61

P31

Q48499411-6DCE718C-D39C-492D-8CB4-02CE4AF59F38

P356

Q48499411-71F4388C-ED2A-446F-8F83-620CF6D81272

P407

Q48499411-019D9454-D7EC-4BDB-ACF4-2B1FFA9766A6

P433

Q48499411-57016FEF-F6B5-4D11-A4FF-026FDB16FDAB

P478

Q48499411-07AF0A6C-9399-49A9-A2DA-DC1103726A84

P50

Q48499411-0D1B4931-39EE-4367-BEF1-12F0566CC2F1

Q48499411-34FBF178-7873-4A0B-BA08-BDD25F928DC7

Q48499411-5639AF39-CCB0-4530-A348-94BE09F5EFE3

Q48499411-64BB3F87-EAC2-433B-8769-195BC15E62E3

Q48499411-6D160B7F-5728-47F7-B843-19D126CCE485

Q48499411-A011CDFF-F0DD-4BB8-8E05-616FACEF87F5

Q48499411-C578DC0A-7C2F-4489-97E4-E1DB8CBBBFCB

Q48499411-CB4C279F-9FC1-42E6-A0D8-D639276DFE02

P577

Q48499411-BB90C4D4-A3D8-4738-9398-332A38928DD1

P5875

Q48499411-3316256E-40BF-4CA4-9126-AABAC9E4E207

P698

Q48499411-75A05C2E-D92A-45D0-92E8-C06988E40C97

P921

Q48499411-CC0ECE77-4F25-46EE-B026-812816F561A3

P356

JCO.2011.41.2452

P1433

Journal of Clinical Oncology

P1476

BRAF/NRAS mutation frequencies ...... ses in patients with melanoma.

@en

P2093

Amelia Lissia

http://www.w3.org/2001/XMLSchema#string

Antonella Manca

http://www.w3.org/2001/XMLSchema#string

Antonio Cossu

http://www.w3.org/2001/XMLSchema#string

Daniela Massi

http://www.w3.org/2001/XMLSchema#string

Elena Pagani

http://www.w3.org/2001/XMLSchema#string

Ester Fonsatti

http://www.w3.org/2001/XMLSchema#string

Maria Colombino

http://www.w3.org/2001/XMLSchema#string

Mariacristina Sini

http://www.w3.org/2001/XMLSchema#string

Nicola Mozzillo

http://www.w3.org/2001/XMLSchema#string

Oscar Nappi

http://www.w3.org/2001/XMLSchema#string

P304

2522-2529

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2011.41.2452

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Mariaelena Capone

Giuseppe Palmieri

Paolo Antonio Ascierto

Corrado Caracò

P577

2012-05-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225054123

http://www.w3.org/2001/XMLSchema#string

P698

22614978

http://www.w3.org/2001/XMLSchema#string

P921